Breast cancer, Secondary cancers
Open
Phase 2
This trial is comparing datopotamab deruxtecan with durvalumab and datopotamab deruxtecan for triple negative breast cancer.
It is for people whose cancer:
has grown into surrounding tissues or spread to another part of the body ()
has low levels of a protein called PD-L1
You pronounce datopotamab deruxtecan as day-toe-pot-oh-mab deh-rux-tee-can.
Recruitment start: 24 October 2025
Recruitment end: 31 March 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
AstraZeneca
Queen Mary University of London
Last reviewed: 15 Apr 2026
CRUK internal database number: 20108
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
